MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

Everything You Wanted To Know About the Pitt-Cal U54 Pharmacokinetics Resource Laboratory

Everything You Wanted To Know About the Pitt-Cal U54 Pharmacokinetics Resource Laboratory

Timothy Synold, PharmD

Clinical Update: Sickle Cell Disease and CRISPR

Clinical Update: Sickle Cell Disease and CRISPR

Sophia Z. Humphreys, PharmD, MHA, BCBBS

Clinical Update: Solid Organ Tumors

Clinical Update: Solid Organ Tumors

Osler Andres, PharmD, BCOP, BCSCP

Development of Pharmacy-Led Ambulatory Infusion Services (Part 3)

Development of Pharmacy-Led Ambulatory Infusion Services (Part 3)

Melissa Casey, PharmD

Development of Pharmacy-Led Ambulatory Infusion Services (Part 2)

Development of Pharmacy-Led Ambulatory Infusion Services (Part 2)

Tamera L. Boeshans, BSPharm

Development of Pharmacy-Led Ambulatory Infusion Services (Part 1)

Development of Pharmacy-Led Ambulatory Infusion Services (Part 1)

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Patient Centered Pharmaceutical Care in Community Setting

Patient Centered Pharmaceutical Care in Community Setting

Melissa Russo, PharmD

Artificial Intelligence (AI): How Can This Technology Supplement the Advanced Role of the Pharmacist?

Artificial Intelligence (AI): How Can This Technology Supplement the Advanced Role of the Pharmacist?

Ashish Advani, PharmD

Clinical Update: Malignant Hematology

Clinical Update: Malignant Hematology

Atis Barzdins, MD

White Bagging & The Movement for Policy Development

White Bagging & The Movement for Policy Development

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Clinical and Practice Considerations in the Management of Iron Deficiency Anemia

Clinical and Practice Considerations in the Management of Iron Deficiency Anemia

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

PD-1 Inhibitor Update

PD-1 Inhibitor Update

Sophia Z. Humphreys, PharmD, MHA, BCBBS

Policy Update - Financial Survival: It’s not Easy Being Green!!

Policy Update - Financial Survival: It’s not Easy Being Green!!

Bonnie Kirschenbaum, BScPharm, MS, FASHP, FCSHP

Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics

Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics

Kerrie B. Lee, PharmD, BCSCP

Clinical Update: Biosimilars to Adalimumab

Clinical Update: Biosimilars to Adalimumab

Johnny Chang, PharmD, BCPS, CSP

The Art and the Science of Formulary Management | Acute to Ambulatory Strategies

The Art and the Science of Formulary Management | Acute to Ambulatory Strategies

Catherine Brown, PharmD, MSM, BCPS & Steve Pickette, PharmD, BCPS

Clinical Update: Cell and Gene Therapy, the Future of Medicine

Clinical Update: Cell and Gene Therapy, the Future of Medicine

Sophia Z. Humphreys, PharmD, MHA, BCBBS

$Sequencing Therapy in Relapsed/Refractory Myeloma Patients$

Sequencing Therapy in Relapsed/Refractory Myeloma Patients

Craig Emmitt Cole, MD

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Saad Usmani, MD, MBA, FACP

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Gabriela S. Hobbs, MD

Acquired Inhibitors in Cancer: State-of-the Art Management

Acquired Inhibitors in Cancer: State-of-the Art Management

Cindy Leissinger, MD

Novel Therapeutic Strategies for MDS Based on Molecular Profile

Rami Komrokji, MD

CAR-T Cell Therapy in Lymphomas: 7-Years Later

CAR-T Cell Therapy in Lymphomas: 7-Years Later

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

De Novo Acute Myeloid Leukemia

De Novo Acute Myeloid Leukemia

Hugo F. Fernandez, MD

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

Brian Primeaux, PharmD, BCOP

CLL: Therapeutic Advances in 2024

CLL: Therapeutic Advances in 2024

Javier Pinilla-Ibarz, MD, PhD

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Nakhle Saba, MD

What Is New for DLBCL and & Hodgkin’s Disease?

What Is New for DLBCL and & Hodgkin’s Disease?

Eduardo Sotomayor, MD

Novel Advances in T-Cell NHL Therapies

Novel Advances in T-Cell NHL Therapies

Luis E. Fayad, MD

Small Cell Lung Cancer: Targeting This Difficult Target

Small Cell Lung Cancer: Targeting This Difficult Target

Anne Chiang, MD, PhD